Gene therapy in combination with tissue engineering to treat epidermolysis bullosa
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
In the last 20 years epidermal stem cells have been extensively used for tissue regeneration of epidermis and other epithelial surfaces. The tremendous progress achieved has led to the development of protocols aimed at the correction of rare genetic disorders such as epidermolysis bullosa (EB), a severe, often lethal, blistering disorder of the skin. Approximately 400,000-500,000 people are affected worldwide and no definitive treatments have yet been developed. Gene therapy might represent an alternative therapeutic approach. This paper reviews the different strategies used to genetically modify keratinocytes from EB patients and addresses issues such as the use of in vivo or ex vivo approaches, how to target keratinocytes with stem cell properties in order to have long-term therapeutic gene expression, and which gene transfer agents should be used. The progress made has led the authors' group to submit a request for a Phase I/II ex vivo therapy clinical trial for patients with junctional EB.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
HIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots
Schröder, A. R. W., Shinn, P., Chen, H., Berry, C., Ecker, J. R., & Bushman, F. (2002) · Cell · doi:10.1016/s0092-8674(02)00864-4 · Cited by 1,832
Blanpain, C., Lowry, W. E., Geoghegan, A., Polak, L., & Fuchs, E. (2004) · Cell · doi:10.1016/j.cell.2004.08.012 · Cited by 1,428 · cited 1×
“Therefore, the holoclone is the smallest colony-founding cell, has the highest proliferative capacity (> 180 doublings) and is considered equivalent to the epithelial stem cell [5-14].”
BackgroundTranscription Start Regions in the Human Genome Are Favored Targets for MLV Integration
Wu, X., Li, Y., Crise, B., & Burgess, S. M. (2003) · Science · doi:10.1126/science.1083413 · Cited by 1,305 · cited 1×
“In fact, whereas retroviruses integrate preferentially near the start site of transcriptional units (either upstream or downstream), an event that has been shown to lead to the activation of protooncogenes, lentiviruses prefer integration anywhere in the transcriptional unit [70-72].”
BackgroundOrtiz-Urda, S., Lin, Q., Yant, S. R., Keene, D., Kay, M. A., & Khavari, P. A. (2003) · Gene Therapy · doi:10.1038/sj.gt.3301978 · Cited by 118
Nucleofection: a new, highly efficient transfection method for primary human keratinocytes*
Distler, J. H. W., Jüngel, A., Kurowska‐Stolarska, M., Michel, B. A., Gay, R. E., Gay, S., & Distler, O. (2005) · Experimental Dermatology · doi:10.1111/j.0906-6705.2005.00276.x · Cited by 53
Cited by
Progress and opportunities for tissue-engineered skin
MacNeil, S. (2007) · Nature · doi:10.1038/nature05664 · Cited by 1,112
Advances in skin grafting and treatment of cutaneous wounds
Sun, B. K., Siprashvili, Z., & Khavari, P. A. (2014) · Science · doi:10.1126/science.1253836 · Cited by 972
Bone Marrow Transplantation for Recessive Dystrophic Epidermolysis Bullosa
Wagner, J. E., Ishida-Yamamoto, A., McGrath, J. A., Hordinsky, M., Keene, D. R., Woodley, D. T., Chen, M., Riddle, M. J., Osborn, M. J., Lund, T., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0910501 · Cited by 374
Artificial skin in perspective: concepts and applications
Brohem, C. A., da Silva Cardeal, L. B., Tiago, M., Soengas, M. S., de Moraes Barros, S. B., & Maria‐Engler, S. S. (2011) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00786.x · Cited by 267
Gene therapy for severe combined immunodeficiency: are we there yet?
Cavazzana-Calvo, M., & Fischer, A. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30953 · Cited by 183
Metadata
- Authors
- Ferrari, S., Pellegrini, G., Matsui, T., Mavilio, F., & De Luca, M.
- Venue
- Expert Opinion on Biological Therapy
- Publisher
- Informa Healthcare
- Published
- 2006-03-21
- Volume
- 6
- Issue
- 4
- Pages
- 367-378
- ISSN
- 1471-2598 (ISSN-L)
- 1744-7682
- OpenAlex
- W1966126358
- Cited by
- 37
- References
- 5
- FWCI
- 2.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.